Vaginal Atrophy: Symptoms, Causes, and Treatment Options That Actually Work

Vaginal atrophy is one of the most common and most undertreated conditions in midlife and older women. Surveys consistently find that more than half of postmenopausal women experience symptoms, but only a small fraction discuss it with their clinician, and an even smaller fraction receives effective treatment. The reasons are partly cultural (women are often reluctant to bring up symptoms involving the vagina, vulva, and urinary tract) and partly clinical (many primary care providers do not proactively screen for these symptoms). The result is years of unnecessary discomfort, painful intercourse, recurrent urinary tract infections, and reduced quality of life when effective, low-risk treatments are available.

What Is Vaginal Atrophy / GSM?

Vaginal atrophy refers to the thinning, drying, and loss of elasticity in vaginal and vulvar tissues that follows declining estrogen levels. The contemporary medical term, genitourinary syndrome of menopause (GSM), is broader and more accurate because the condition affects not just the vagina but also the vulva, urethra, bladder, and pelvic floor. The renaming, formalized in 2014 by the International Society for the Study of Women’s Sexual Health and the Menopause Society, reflects the recognition that this is a syndrome involving multiple anatomically connected tissues rather than a single localized problem.

Estrogen receptors are abundant throughout the urogenital tract. The vaginal walls, vulvar tissues, urethra, bladder trigone, and pelvic floor muscles all express estrogen receptors and respond to estrogen levels. When estrogen declines, these tissues lose thickness, hydration, elasticity, and protective glycogen content. The vaginal microbiome shifts, with the loss of glycogen-fermenting Lactobacillus species that maintain the protective acidic vaginal pH. The protective changes that estrogen maintained in reproductive years are gradually lost, and the symptoms that follow reflect that loss.

What the Symptoms Actually Feel Like

The symptoms of GSM extend well beyond the “vaginal dryness” label that often appears in patient handouts. The full picture often includes vaginal dryness with a sensation of constant irritation, sometimes described as feeling like there is sand or sandpaper in the vagina or on the vulva. Burning or stinging sensations, especially after intercourse, after using bath products, or after wiping with toilet paper. Vulvar tissues that look thin, pale, and lacking the natural pink color and fullness of healthy tissue. Painful intercourse, sometimes severe enough that intercourse becomes impossible or is avoided entirely. Tears, fissures, or small cuts that develop with intercourse and take a long time to heal.

The urinary symptoms are equally significant and often less recognized as part of the same syndrome. Urinary urgency, the sensation of needing to urinate even when the bladder is not full. Urinary frequency, including waking multiple times at night to urinate. Recurrent urinary tract infections, often without identifiable behavioral cause. Discomfort with urination, including stinging or burning that can be mistaken for a UTI when no infection is present. Stress incontinence, leaking urine with cough, sneeze, or exercise, can also worsen as the urethral tissues thin and pelvic floor support diminishes. The bladder side of this has its own guide, including why systemic hormone therapy is not the treatment for urinary incontinence in menopause.

Beyond the local symptoms, the broader effects on quality of life are substantial. Sexual function is affected directly through pain and indirectly through anticipatory anxiety. Intimate relationships strain when intercourse becomes painful and is avoided. Daily comfort suffers from chronic irritation. Sleep is disrupted by nocturia. Confidence in physical activity decreases when stress incontinence develops. Each of these effects compounds over time without treatment.

Why GSM Progresses Without Treatment

Unlike vasomotor symptoms (hot flashes, night sweats), which often improve over years even without treatment, GSM does not resolve on its own. The tissues are responding to ongoing estrogen deficiency, and as long as that deficiency persists, the changes continue. Many women in their 60s, 70s, and beyond have more severe GSM than they did at 55, not less. The progression is gradual but consistent, and the longer the tissues are estrogen-deprived, the more thinned and fragile they become, and the harder it is to restore them with treatment.

This is one of the reasons earlier treatment produces better outcomes. Tissues that have been estrogen-deprived for 5 years respond more readily to local estrogen than tissues that have been deprived for 20 years. Recurrent UTIs that have been recurring for a decade are harder to break the cycle on than UTIs that started 6 months ago. The clinical principle is similar to other midlife conditions: earlier intervention works better than late intervention, and the absence of dramatic symptoms in the first few years should not be mistaken for the absence of progressing disease.

Treatment Options

Several effective treatments exist for GSM, and the right choice depends on the woman’s symptom severity, overall HRT picture, and any specific contraindications.

Local vaginal estrogen. The first-line treatment for GSM is low-dose vaginal estradiol delivered as a cream (Estrace cream, Premarin cream), tablet (Vagifem, Yuvafem), or ring (Estring). These produce minimal systemic absorption (most products produce blood estradiol levels well below the typical premenopausal range) and act primarily on the local tissues. Treatment typically begins with daily application for 1 to 2 weeks (the loading phase), then transitions to twice-weekly maintenance dosing indefinitely. Most women notice meaningful improvement within 2 to 4 weeks, with full tissue restoration typically achieved by 12 weeks of consistent use. ACOG Practice Bulletin on management of menopausal symptoms recognizes local vaginal estrogen as first-line treatment for GSM.

DHEA vaginal inserts (Intrarosa). Prasterone, a vaginal DHEA insert, is an FDA-approved alternative to vaginal estrogen for moderate to severe dyspareunia (painful intercourse). It is converted locally to estradiol and testosterone within the vaginal cells, with minimal systemic effect. May be appropriate for women who cannot tolerate vaginal estrogen or whose symptom picture warrants a different approach.

Ospemifene (Osphena). An oral selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on vaginal tissues. Taken as a daily tablet rather than vaginally. May be useful for women who prefer oral medication or who have difficulty with vaginal application.

Femring. A vaginal ring that releases higher-dose estradiol producing systemic levels comparable to oral or transdermal HRT, while also treating local symptoms. Useful for women who want both systemic HRT and GSM treatment in a single device.

Non-hormonal options. Vaginal moisturizers (Replens, Hyalo Gyn, others) used regularly several times per week provide some symptom relief without hormones. Lubricants (silicone, water, or oil-based) used during intercourse address the friction component of pain. These do not reverse the underlying tissue changes but can be useful adjuncts or alternatives for women who cannot use any form of hormone therapy. Vaginal hyaluronic acid preparations are increasingly available and produce modest tissue improvement.

Vaginal lasers and energy-based devices. Fractional CO2 laser therapy and other energy-based devices have been marketed for GSM and produce some tissue improvement in some patients, but the evidence base is less robust than for vaginal estrogen, and the FDA has issued safety communications about marketing claims for some of these devices. Generally considered after first-line options have been tried or for specific patients.

Why Recurrent UTIs Often Respond to Vaginal Estrogen

One of the underappreciated indications for vaginal estrogen is recurrent urinary tract infection prevention in postmenopausal women. The mechanism involves restoring the protective vaginal microbiome (specifically the Lactobacillus species that maintain acidic vaginal pH), thickening the urethral tissues that normally provide a barrier to ascending bacteria, and improving local immune function in the urogenital tract. Multiple randomized trials have demonstrated that low-dose vaginal estrogen significantly reduces UTI frequency in women with recurrent infections, often with magnitude of effect comparable to or greater than prophylactic antibiotics, and without the antibiotic resistance concerns of long-term suppressive antibiotic use.

Women with three or more UTIs in a year, particularly women whose UTIs developed or worsened after menopause, should be evaluated for GSM as a potential underlying contributor. Treating the GSM often reduces UTI frequency dramatically, sometimes eliminating recurrent UTIs entirely.

How Vaginal Estrogen Differs From Systemic HRT

One of the most important clinical points for patients to understand is that local vaginal estrogen is not the same as systemic HRT in either its effects or its risk profile. Low-dose vaginal estradiol produces minimal absorption into the bloodstream. Most women on standard low-dose vaginal estrogen have systemic estradiol levels essentially indistinguishable from non-users, and the cardiovascular, breast cancer, and clotting concerns that apply to systemic HRT do not apply at the same magnitude to local vaginal preparations.

This means many women who cannot or do not want systemic HRT can still safely use vaginal estrogen for GSM symptoms. Women with prior breast cancer (after oncology consultation), women with cardiovascular disease, women on tamoxifen, and women who simply do not want systemic hormones can often use vaginal estrogen safely with substantial quality-of-life benefit. The 2022 NAMS position statement, available at the Menopause Society NAMS HRT position statement page, explicitly recognizes vaginal estrogen as having a different risk profile than systemic HRT.

What to Expect on Treatment

For women starting low-dose vaginal estrogen, the typical timeline of improvement looks like this. Within 2 weeks, dryness and irritation often begin to improve. By 4 weeks, painful intercourse is often substantially better. By 8 to 12 weeks, urinary symptoms (urgency, frequency, recurrent UTI vulnerability) typically improve. Tissue appearance on examination shows visible improvement (better color, thickness, hydration) over the same 8 to 12 week window. Maintenance dosing twice weekly is then continued indefinitely; stopping treatment reverses the gains within months as the tissues return to the estrogen-deprived state.

The treatment is not a cure in the sense of producing permanent change. It is ongoing replacement of the local hormone the tissues need to remain healthy. This is the same model as systemic HRT for systemic symptoms, and the implication is the same: the treatment continues for as long as the symptoms would return without it, which for most women means indefinite use.

The Importance of Talking About It

One of the practical barriers to treatment is that women often do not bring up GSM symptoms with their clinician, and many clinicians do not proactively screen for them. The result is that women with significant symptoms continue without treatment, often assuming it is a normal part of aging that they should accept. The honest clinical reality is that GSM is treatable, the treatments work, and the impact on quality of life of treating it is substantial. Bringing up the symptoms matters, even if the conversation feels awkward.

Current evidence supports initiating HRT within 10 years of the menopausal transition, or before age 60, for the most favorable benefit-to-risk profile, but local vaginal estrogen for GSM does not follow the same timing principle. It can be started at any age, in any year past menopause, and the response is generally favorable regardless of how many years of GSM have preceded treatment. The WHI studied oral conjugated equine estrogen plus medroxyprogesterone acetate, not the modern formulations of low-dose vaginal estradiol used today, and the WHI risk findings do not apply to local vaginal estrogen at the doses currently used.

The Bottom Line

Vaginal atrophy, more accurately called genitourinary syndrome of menopause, affects more than half of postmenopausal women but is treated in only a fraction of them. The symptoms (vaginal dryness, painful intercourse, urinary urgency, recurrent UTIs) progress without treatment, not toward natural resolution. Local vaginal estrogen is highly effective, has minimal systemic absorption, and is generally considered safe in most women including many breast cancer survivors after specialist consultation. Non-hormonal options exist for women who cannot use estrogen. The biggest barrier to effective treatment is often the conversation itself, and the practical step that helps most is naming the symptoms specifically with a clinician who treats GSM as the legitimate clinical condition it is.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on hormone therapy, medical weight loss, and aesthetics. Sugar Hill, GA and telehealth for Georgia patients.